This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jayagopal, V. Articles by Atkin, S. L. Search for Related Content PubMed PubMed Citation Articles by Jayagopal, V. Articles by Atkin, S. L.

The Biological Variation of Insulin Resistance in Polycystic Ovarian Syndrome

Department of Medicine, University of Hull (V.J., S.L.A.), York District General Hospital (P.E.J.), and Department of Clinical Biochemistry and Immunology, Hull Royal Infirmary (E.S.K., S.H.), Hull, United Kingdom HU3 2RW

Address all correspondence and requests for reprints to: Dr. V. Jayagopal, University of Hull, Michael White Center for Diabetes and Endocrinology, Hull Royal Infirmary, Anlaby Road, Hull, United Kingdom HU3 2RW. E-mail: . v.jayagopal{at}hull.ac.uk

Abstract

Increased insulin resistance (IR) is a cardinal feature of overweight patients with polycystic ovarian syndrome (PCOS). However, there are no data on the variability of IR for subjects with PCOS. The biological variation of IR (homeostasis model assessment model) was assessed by measuring IR at 4-d intervals on 10 consecutive occasions in 12 overweight PCOS patients (median age, 28 yr; range, 18–31 yr) and 11 weight-matched control women having regular menses and without PCOS (median age, 30 yr; range, 19–33 yr). The distribution of IR was log Gaussian in PCOS and Gaussian distribution in the control group. The IR in PCOS subjects was significantly greater than in the controls [mean (range), 5.85 U (1–42.1) vs. 1.67 U (0.48–3.49); P = 0.001]. After accounting for analytical variation, the mean intraindividual variance was also substantially greater in PCOS patients than in controls (mean, 1.19 vs. 0.23). As a consequence, at any level of IR, a subsequent sample must rise by more than 322% or fall by more than 31% to be considered significantly different from the first. IR, measured using the homeostasis model assessment model, is significantly greater and more variable for overweight patients with PCOS. Therefore, this inherent variability needs to be accounted for in studies of IR in PCOS.

This article has been cited by other articles:

				L. W. Cho, V. Jayagopal, E. S. Kilpatrick, and S. L. Atkin The Biological Variation of C-Reactive Protein in Polycystic Ovarian Syndrome Clin. Chem., October 1, 2005; 51(10): 1905 - 1907. [Full Text] [PDF]

				C. Ortega-Gonzalez, S. Luna, L. Hernandez, G. Crespo, P. Aguayo, G. Arteaga-Troncoso, and A. Parra Responses of Serum Androgen and Insulin Resistance to Metformin and Pioglitazone in Obese, Insulin-Resistant Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1360 - 1365. [Abstract] [Full Text] [PDF]

				V. Jayagopal, E. S. Kilpatrick, S. Holding, P. E. Jennings, and S. L. Atkin Orlistat Is as Beneficial as Metformin in the Treatment of Polycystic Ovarian Syndrome J. Clin. Endocrinol. Metab., February 1, 2005; 90(2): 729 - 733. [Abstract] [Full Text] [PDF]

				V. Jayagopal, E. S. Kilpatrick, P. E. Jennings, D. A. Hepburn, and S. L. Atkin The Biological Variation of Testosterone and Sex Hormone-Binding Globulin (SHBG) in Polycystic Ovarian Syndrome: Implications for SHBG as a Surrogate Marker of Insulin Resistance J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1528 - 1533. [Abstract] [Full Text] [PDF]